Early administered antibiotics do not impact mortality in critically ill patients with COVID-19.

  11 June 2020

COVID-19 may mimic bacterial pneumonia and, therefore, antibiotics for possible bacterial coinfection were frequently administered. We conducted a retrospective analysis aimed at describing the impact of early antibiotic therapy (i.e., before intensive care unit [ICU] admission) on mortality and delayed severe healthcare-associated infections in the ICU.

However, our preliminary results illustrate that early administered antibiotics do not appear to significantly impact mortality or delayed hospital-acquired infections in critically ill patients and call into question the utility of early treatment of a presumptive bacterial superinfection in COVID-19 patients. Large multi-centric studies are urgently needed to investigate the impact of early antibiotics therapy on mortality, subsequent healthcare associated infections and ICU complications (i.e., duration of mechanical ventilation).

Further reading: Journal of Infection
Author(s): Niccolò Buetti, MDMSc Timothy Mazzuchelli Elia Lo Priore, MD Pierpaolo Trimboli, MDProf Valentina Forni-Ogna, MD Enos Bernasconi, MDProf et al
Effective Surveillance   Healthy Patients  

Display your AMR technology / product:

Global AMR Technologies Database

  • Preventive – Diagnostic – Antimicrobial technologies
  • Academia – Research Institutes – Start ups – SMEs – Multinationals
  • Early research <-> near market
  • Global reach for funding / co-development / licensing
Display your technology and make use of the Continuous AMR Partnering Initiative >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!